EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
作者：
Douillard, Jean-Yves [1 ]
Ostoros, Gyula [2 ]
Cobo, Manuel [3 ]
Ciuleanu, Tudor [4 ]
Mccormack, Rose [7 ]
Webster, Alan [5 ]
Milenkova, Tsveta [6 ]
机构：
[1] Ico R Gauducheau, St Herblain, France
[2] Koranyi Natl Inst Tb & Pulmonol, Budapest, Hungary
[3] Hru Carlos Haya, Malaga, Spain
[4] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania
[5] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[6] Astrazeneca, Res & Dev, Cambridge, England
[7] Astrazeneca, Personalised Healthcare, Luton, Beds, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutation; gefitinib; NSCLC; Caucasian; circulating-free DNA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-020
引用
收藏
页码：S1194 / S1195
页数：2
相关论文
共 50 条
[21]   AN ADMINISTRATION TIMING AND DOSAGE OF THE GEFITINIB IN THE ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION [J].
Fujimoto, Sakae ;
Miura, Yosuke ;
Yoshida, Tsutomu ;
Fujita, Atsushi ;
Minato, Kouichi .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S1164-S1164
[22]   FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY [J].
Wu, Yi-Long ;
Liam, Chong-Kin ;
Zhou, Caicun ;
Wu, Gang ;
Liu, Xiaoqing ;
Zhong, Zhaoyang ;
Lu, Shun ;
Cheng, Ying ;
Han, Baohui ;
Chen, Lei ;
Zhu, Yunzhong ;
Qin, Shukui ;
Huang, Cheng ;
Pan, Hongming ;
Liang, Houjie ;
Li, Enxiao ;
How, Soon Hin ;
Jiang, Guoliang ;
Cherry, Marie ;
Fernando, Lynn ;
Chen, Meng ;
Zuo, Yunxia ;
Ladrera, Guia .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S603-S604
[23]   Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer [J].
Laura Ortega-Granados, Ana ;
Artal-Cortes, Angel ;
Aguiar-Bujanda, David ;
Oramas, Juana ;
Luis Firvida, Jose ;
De Castro, Javier ;
Campillo Fuentes, Juana ;
Gordo, Rocio ;
Galan, Raquel ;
Trigo, Jose .
ANTICANCER RESEARCH, 2019, 39 (03) :1317-1328
[24]   First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting [J].
Park, Keunchil ;
Lim, Darren Wan-Teck ;
Okamoto, Isamu ;
Yang, James Chih-Hsin .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
[25]   ERLOTINIB AFTER FAILURE OF GEFITINIB THERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH OR WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION [J].
Saito, Hiroshi ;
Kimura, Tomoki ;
Abe, Takashi ;
Kondo, Masashi ;
Ogasawara, Tomohiko ;
Tanikawa, Yoshimasa ;
Yokoyama, Toshihiko ;
Kojima, Eiji ;
Yamamoto, Masashi ;
Suzuki, Ryujiro .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1210-S1211
[26]   Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer [J].
Kimura, M. ;
Yasue, F. ;
Usami, E. ;
Kawachi, S. ;
Iwai, M. ;
Go, M. ;
Ikeda, Y. ;
Yoshimura, T. .
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) :201-206
[27]   Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues [J].
Gridelli, C. ;
De Marinis, F. ;
Di Maio, M. ;
Cortinovis, D. ;
Cappuzzo, F. ;
Mok, T. .
LUNG CANCER, 2011, 72 (01) :3-8
[28]   Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study [J].
Lu, Shun ;
Zhou, Jian-Ying ;
Niu, Xiao-Min ;
Zhou, Jian-Ya ;
Jian, Hong ;
Yin, Hong-Yan ;
Guan, Sha ;
Wang, Lin-Fang ;
Li, Ke ;
He, James ;
Su, Wei-Guo .
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) :839-+
[29]   Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience [J].
Chu, Q. ;
Agha, A. ;
Devost, N. ;
Walton, R. N. ;
Ghosh, S. ;
Ho, C. .
CURRENT ONCOLOGY, 2020, 27 (01) :27-33
[30]   EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ASIAN AND EUROPEAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) [J].
Lopes, Gilberto D. L., Jr. ;
Segel, Joel ;
Tan, Daniel ;
Do, Young ;
Novello, Silvia ;
Mok, Tony ;
Scagliotti, Giorgio ;
Finkelstein, Eric .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1179-S1179
12345